This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Ironwood Amends Linzess Agreement with AstraZeneca in China
by Zacks Equity Research
Ironwood (IRWD) announces amendment in collaboration agreement with AstraZeneca, granting the latter exclusive rights to develop, manufacture and commercialize Linzess in China.
Ardelyx Gets FDA Approval for Ibsrela As IBS-C Treatment
by Zacks Equity Research
Ardelyx (ARDX) gets first-ever FDA approval for its pipeline candidate, tenapanor, as a treatment for irritable bowel syndrome with constipation in adults. It will be available under the tradename Ibsrela.
Ardelyx (ARDX) in Focus: Stock Moves 8.3% Higher
by Zacks Equity Research
Ardelyx (ARDX) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.
Ardelyx (ARDX) Gains on Tenapanor's Success in Pivotal Study
by Zacks Equity Research
Ardelyx's (ARDX) lead pipeline candidate, tenapanor, meets primary endpoint in a pivotal phase III study.
Biotech Stock Roundup: REGN Wins Against AMGN, VRTX to Acquire Semma & More
by Ekta Bagri
Key highlights of the past week include litigation updates, acquisitions, and other regulatory and pipeline updates.
Ardelyx (ARDX) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Ardelyx (ARDX) delivered earnings and revenue surprises of -5.13% and -97.00%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Ardelyx (ARDX) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
by Zacks Equity Research
Ardelyx (ARDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ardelyx (ARDX) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Ardelyx (ARDX) delivered earnings and revenue surprises of -10.53% and -100.00%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Ardelyx (ARDX) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Ardelyx (ARDX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What's in the Cards for Axon Enterprise (AAXN) Earnings?
by Zacks Equity Research
Axon Enterprise's (AAXN) expanded product offerings and strong execution likely to drive its first-quarter 2019 performance.
What's in Store for Penumbra (PEN) This Earnings Season?
by Zacks Equity Research
Penumbra (PEN) deepens focus on driving innovation, ramping up production and expanding geographies.
Can Dental Growth Drive Henry Schein's (HSIC) Q2 Earnings?
by Zacks Equity Research
Henry Schein (HSIC) is strongly placed to gain from the ongoing trend of digitalization in the global dental market.
Top Ranked Momentum Stocks to Buy for July 26th
by Zacks Equity Research
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, July 26th:
Top Ranked Momentum Stocks to Buy for July 24th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, July 24th:
Top Ranked Momentum Stocks to Buy for July 23rd
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, July 23rd:
Zacks.com highlights: Sanchez Midstream Partners, Tecnoglass, Aeterna Zentaris, Ardelyx and Matrix Service
by Zacks Equity Research
Zacks.com highlights: Sanchez Midstream Partners, Tecnoglass, Aeterna Zentaris, Ardelyx and Matrix Service
5 Great Breakout Stocks Offering Superlative Returns
by Swarup Gupta
This method involved zeroing in on those stocks whose prices are varying within a narrow band.
Can The Uptrend Continue for Ardelyx (ARDX)?
by Zacks Equity Research
Investors certainly have to be happy with Ardelyx Inc (ARDX) and its short term performance
Why Ardelyx (ARDX) Could Beat Earnings Estimates Again
by Zacks Equity Research
Ardelyx (ARDX) boasts a favorable Zacks Rank and a positive Earnings ESP, which is a great sign of a coming earnings beat.
Zacks.com featured highlights: Akari Therapeutics, Joint, Tailored Brands, Ardelyx and BioTime
by Zacks Equity Research
Zacks.com featured highlights: Akari Therapeutics, Joint, Tailored Brands, Ardelyx and BioTime
5 Affordable Breakout Stocks Offering Excellent Returns
by Swarup Gupta
If properly implemented, such a strategy has the ability to deliver impressive returns.
Ardelyx IBS-C Candidate Succeeds in Pivotal Study, Stock Up
by Zacks Equity Research
Ardelyx's (ARDX) tenapanor reduces abdominal pain and improves bowel movements in a phase III study evaluating the drug in irritable bowel syndrome with constipation.
Catalyst (CPRX) Shows Strength: Stock Adds 9.6% in Session
by Zacks Equity Research
Catalyst Pharmaceuticals, Inc. (CPRX) shares rose around 10% in the last trading session.
Zacks.com featured highlights: Ardelyx, Novavax, BioScrip, Layne Christensen and Resonant
by Zacks Equity Research
Zacks.com featured highlights: Ardelyx, Novavax, BioScrip, Layne Christensen and Resonant
5 Breakout Stocks Offering Phenomenal Returns
by Swarup Gupta
This approach involves homing in on stocks trading within a tight range and buying them when they step out of this band.